Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 18/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.65 |
| ▸ | KIT | P10721 | 7/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.48 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.48 |
| ▸ | PLK4 | O00444 | 2/20 | 0.48 |
| ▸ | STK25 | O00506 | 2/20 | 0.48 |
| ▸ | RIOK3 | O14730 | 2/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.48 |
| ▸ | GAK | O14976 | 2/20 | 0.48 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.48 |
| ▸ | MUSK | O15146 | 2/20 | 0.48 |
| ▸ | EPHB6 | O15197 | 2/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.48 |
| ▸ | MAP3K13 | O43283 | 2/20 | 0.48 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.48 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.48 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.48 |
| ▸ | JAK2 | O60674 | 2/20 | 0.48 |
| ▸ | ULK1 | O75385 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2913494 | 0.90 | CSF1R (0.55) | CSF1RCYP2C19KITCYP3A4BMPR1B | |
| SCHEMBL2913489 | 0.89 | CSF1R (0.67) | CSF1RCYP2C19KITCYP3A4BMPR1B | |
| SCHEMBL5260899 | 0.86 | CSF1R (0.54) | CSF1RCYP2C19KITCYP3A4BMPR1B | |
| SCHEMBL3173780 | 0.85 | CSF1R (0.65) | CSF1RCYP2C19KITCYP3A4BMPR1B | |
| Trifluoroacetic Acid SCHEMBL3081621 | 0.84 | CSF1R (0.55) | CSF1RCYP2C19KITCYP3A4BMPR1B | |
| SCHEMBL2909875 | 0.84 | KIT (0.52) | CSF1RCYP2C19KITCYP3A4BMPR1B | |
| SCHEMBL3173704 | 0.84 | CSF1R (0.64) | CSF1RCYP2C19KITCYP3A4BMPR1B | |
| SCHEMBL2913128 | 0.83 | CSF1R (0.64) | CSF1RCYP2C19KITCYP3A4BMPR1B | |
| Trifluoroacetic Acid SCHEMBL3081618 | 0.82 | CSF1R (0.53) | CSF1RCYP2C19KITCYP3A4BMPR1B | |
| SCHEMBL3086038 | 0.82 | CSF1R (0.63) | CSF1RCYP2C19KITCYP3A4NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662837-B2 | 4-cyano-1H-imidazole-2-carboxylic acid {2-cyclohex-1-enyl-4-[1-(2-dimethylamino-acetyl)-piperidin-4-yl]-phenyl}-amide; protein tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-16 | — | — | US | claimed |
| US-7645755-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICAL N.V. (BE) | 2010-01-12 | — | — | US | claimed |
| EP-1807077-A2 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-18 | — | — | EP | claimed |
| US-20060189623-A1 | Inhibitors of c-fms kinase | ILLIG CARL R | 2006-08-24 | — | — | US | claimed |
| US-20060148812-A1 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-06 | — | — | US | claimed |
| WO-2006047277-A2 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-04 | — | — | WO | claimed |
| US-10806737-B2 | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides | ARVINAS OPERATIONS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20180256586-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2018-09-13 | — | — | US | disclosed |
| US-9526731-B2 | Method of inhibiting C-KIT kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-12-27 | — | — | US | disclosed |
| EP-1807077-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-23 | — | — | EP | disclosed |
| US-20150094520-A1 | METHOD OF INHIBITING C-KIT KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-02 | — | — | US | disclosed |
| US-8933091-B2 | Method of inhibiting C-KIT kinase | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-13 | — | — | US | disclosed |
| US-8697716-B2 | Method of inhibiting C-KIT kinase | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-15 | — | — | US | disclosed |
| US-20070149572-A1 | METHOD OF INHIBITING FLT3 KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-28 | — | — | US | disclosed |
| WO-2007048088-A2 | METHOD OF INHIBITING FLT3 KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-26 | — | — | WO | disclosed |
| WO-2006138155-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-28 | — | — | WO | disclosed |
| US-20060281788-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
| US-20060189623-A1 | Inhibitors of c-fms kinase | ILLIG CARL R | 2006-08-24 | — | — | US | disclosed |
| US-20060148812-A1 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-06 | — | — | US | disclosed |
| WO-2006047277-A2 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189623-A1 | Inhibitors of c-fms kinase | MUSK, TYK2, FES | CSF1R 34/4885CYP2C19 3150/4885KIT 125/4885 |
| US-20180256586-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES | MDM2, CRBN, FLT3 | CSF1R 806/4885CYP2C19 4600/4885KIT 557/4885 |
| US-20060281788-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | FLT3, MCL1, CSF1R | CSF1R 3/4885CYP2C19 2318/4885KIT 70/4885 |
| US-20060148812-A1 | Inhibitors of c-fms kinase | MUSK, TYK2, FES | CSF1R 34/4885CYP2C19 3150/4885KIT 125/4885 |
| US-10806737-B2 | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides | MDM2, CRBN, FLT3 | CSF1R 806/4885CYP2C19 4600/4885KIT 557/4885 |
| US-20070149572-A1 | METHOD OF INHIBITING FLT3 KINASE | FLT3, PLK1, PHKG1 | CSF1R 149/4885CYP2C19 4377/4885KIT 192/4885 |
| US-20150094520-A1 | METHOD OF INHIBITING C-KIT KINASE | KIT, CHUK, MAP3K13 | CSF1R 2973/4885CYP2C19 4271/4885KIT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.